RA Capital, OrbiMed join autoimmune disorder biotech's $80M round

A local biotech is rethinking how to treat autoimmune diseases. It's raised $80 million to do it.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 1, 2020 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news